礼来(LLY)股票3月5日盘中下跌3.19%:背后推手曝光

TradingKey中文
Mar 06

礼来 (LLY) 盘中下跌3.19%, 所属行业医药与医学研究下跌2.91% ,公司涨幅跑输行业涨幅,行业成交额前三股票 礼来 (LLY) 下跌 3.19%;强生 (JNJ) 下跌 3.42%;艾伯维 (ABBV) 下跌 2.89%。

礼来(LLY)技术分析

礼来 (LLY) 技术面来看,MACD(12,26,9)数值[-5.59],处于卖出状态,RSI数值44.11处于中性状态,Williams%R数值-86.49处于超卖状态,注意关注。

礼来(LLY)基本面分析

礼来 (LLY) 处于医药与医学研究行业,最新年度营业收入$65.18B,处于行业4,净利润$20.64B,处于行业2。“公司简介”

近一月多位分析师给出公司评级为买入。目标价预测平均价为$1206.10,最高价为$1500.00,最低价为$875.00。

关于礼来(LLY)的更多详情

公司特定风险:

  • 汇丰银行近期将评级双重下调至“减持”并大幅下调目标价,理由是极度的估值担忧,且认为该股“定价已反映完美预期”,存在极高的不及预期风险。
  • 由于诺和诺德宣布下调竞争性减肥药价格,GLP-1 市场竞争压力加剧并面临价格战风险,这可能会侵蚀礼来 Zepbound 的利润率。
  • 库存膨胀和潜在渠道压货的迹象,表现为平均库存处理周期和应收账款余额显著增加,这预示着未来销售可能放缓或面临库存减记。

原文链接

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10